Synlogic (STU:MIN) Valuation Rank


STU:MIN Synlogic Inc STU:MIN
28 GF Score
Price €3.63
GF Value €0.16
! 1 Warning Sign
View Full Analysis

What is Synlogic Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Synlogic Valuation Rank Related Terms

STU:MIN
28GF Score
Synlogic Inc STU:MIN
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Synlogic (STU:MIN) Overvalued in 2026?

Based on GuruFocus' analysis, Synlogic stock appears to be overvalued. The current stock price of €3.63 is trading 2168.8% above its estimated GF Value™ of €0.16.

Key valuation signals for STU:MIN:

  • Valuation Rank:
  • GF Value™: €0.16 vs. price of €3.63 (2168.8% above fair value)
  • GF Score™: 28/100 with 1 warning sign

No single metric tells the full story. See the STU:MIN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Synlogic Business Description

Other Exchanges SYBX:USA0A8U:UK
Address PO Box 30, Winchester, MA, USA, 01890
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. The pipeline drug candidates includes: labafenogene marselecobac (SYNB1934); SYNB1353 Classical Homocystinuria (HCU); SYNB8802 Enteric Hyperoxaluria; and SYNB2081 Gout. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one operating segment: Discovery and development of Synthetic Biotics.
28GF Score

Get the complete analysis for STU:MIN

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.63
Price
€0.16
GF Value